Abbott Laboratories Reports Strong Q2 2026 Results and Raises Full-Year EPS Guidance

Details

The company reported GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31. Abbott raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, up from the previous range of $5.38 to $5.58. The company also highlighted strong growth in its Diagnostics and Medical Devices segments, with notable contributions from its Diabetes Care and Cancer Diagnostics businesses. Additionally, Abbott provided updates on its clinical trials and product launches, including the completion of enrollment in its TECTONIC U.S. pivotal trial and the CE Mark approval for its Libre Duo biowearable sensor.

Items reported

About Abbott Laboratories

Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.